You are here

Special Protocol Assessment Completed for Allovectin-7

SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- Vical Incorporated (NASDAQ:VICL) today announced that it has successfully completed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a Phase 3 trial of high-dose (2 mg) Allovectin-7 for certain patients with metastatic melanoma. The SPA specifies the trial objectives and design, clinical endpoints, and planned analyses that would be needed to apply for product approval.

The Phase 3, open-label, multi-center trial calls for enrollment of approximately 375 patients with recurrent metastatic melanoma. Patients may have been treated with surgery, adjuvant therapy, and/or biotherapy, but cannot have been treated with chemotherapy. The patients will be randomized on a 2:1 basis: approximately 250 patients will be treated with Allovectin-7 and approximately 125 will be treated with their physician's choice of either of two chemotherapy agents, dacarbazine or temozolomide. The primary endpoint is a comparison of objective response rates at 24 weeks or more after randomization. The study will also evaluate safety and tolerability.

"We are pleased to have reached an agreement with the FDA for a feasible trial design featuring achievable endpoints and providing a clear path to approval," said Mr. Samant. "Now we can advance in our discussions with potential partners and evaluate which, if any, is best positioned to assist with the further development and commercialization of Allovectin-7."

Source: Vical, Inc.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients